Literature DB >> 21882923

Long-term social outcome in children with moyamoya disease who have reached adulthood.

Ji Hoon Phi1, Kyu-Chang Wang, Byung-Kyu Cho, Myung Sook Lee, Jong-Hwa Lee, Kyung-Sang Yu, Bong-Jin Hahm, Seung-Ki Kim.   

Abstract

OBJECT: Although the reported surgical outcome is favorable, there is little information regarding the long-term quality of life in pediatric patients with moyamoya disease (MMD) when they grow to adulthood. The authors conducted a survey to provide details of social adaptation and satisfaction in adults who underwent revascularization surgery for MMD during childhood.
METHODS: One hundred twenty-three patients with MMD who had undergone surgery during childhood and were older than 18 years of age were recruited for this study. The authors mailed self-administered questionnaires regarding each patient's education, employment, marriage, driver's license, physical condition, and satisfaction. Sixty-five patients (53%) responded.
RESULTS: Compared with the general population, the patients showed a similar rate of attaining a higher education. Forty-nine (80%) of 61 patients who were not currently high school students had entered college or university. However, the presence of neurological deficits on preoperative examination was a negative predictor of entrance into a college or university, as well as employment. Some patients had difficulty in planning marriage because of physical handicaps, and the rate of acquiring a driver's license and actual driving were relatively low. Approximately 80% of the responders were satisfied with their treatment outcomes, but more than one-half reported subjectively assessed neurological problems.
CONCLUSIONS: In this study, pediatric patients with MMD showed favorable social adaptation in adulthood. The findings also indicated that early diagnosis and intervention before the establishment of neurological deficits are essential to children with MMD in becoming better socially adapted. Further, more thorough clinical examinations are required during follow-up in patients with MMD.

Entities:  

Mesh:

Year:  2011        PMID: 21882923     DOI: 10.3171/2011.6.PEDS10578

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  7 in total

1.  Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management.

Authors:  Sherif Rashad; Miki Fujimura; Kuniyasu Niizuma; Hidenori Endo; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2016-05-16       Impact factor: 3.042

Review 2.  Cognitive Outcome of Pediatric Moyamoya Disease.

Authors:  Kyu-Won Shim; Eun-Kyung Park; Ju-Seong Kim; Dong-Seok Kim
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

3.  Long-term Outcome of Motor Function in a Child with Moyamoya Disease: A Case Report.

Authors:  Ki Seok Nam
Journal:  J Phys Ther Sci       Date:  2014-01-08

Review 4.  Moyamoya Disease: Treatment and Outcomes.

Authors:  Tackeun Kim; Chang Wan Oh; Jae Seung Bang; Jeong Eun Kim; Won-Sang Cho
Journal:  J Stroke       Date:  2016-01-29       Impact factor: 6.967

Review 5.  Late Cerebrovascular Events and Social Outcome after Adolescence: Long-term Outcome of Pediatric Moyamoya Disease.

Authors:  Takeshi Funaki; Jun C Takahashi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-05-21       Impact factor: 1.742

6.  Characterizing the neurocognitive profiles of children with moyamoya disease using the Das Naglieri cognitive assessment system.

Authors:  Yusuke Kusano; Takeshi Funaki; Keita Ueda; Noyuri Nishida; Kanade Tanaka; Susumu Miyamoto; Shuichi Matsuda
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

Review 7.  A new horizon of moyamoya disease and associated health risks explored through RNF213.

Authors:  Akio Koizumi; Hatasu Kobayashi; Toshiaki Hitomi; Kouji H Harada; Toshiyuki Habu; Shohab Youssefian
Journal:  Environ Health Prev Med       Date:  2015-12-10       Impact factor: 3.674

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.